Reuters logo
BRIEF-Cempra reports anti-nash effects of Solithromycin interim results from phase 2 study
September 29, 2016 / 8:21 PM / a year ago

BRIEF-Cempra reports anti-nash effects of Solithromycin interim results from phase 2 study

Sept 29 (Reuters) - Cempra Inc :

* Nash effects of solithromycin: interim results from phase 2 study

* Cempra Inc says all six patients showed alt reductions after 90 days of treatment with Solithromycin

* Cempra Inc says pre/post treatment biopsies confirm mean nas reduction of 1.3 points after 90 days of treatment with solithromycin

* Cempra inc says Solithromycin was well tolerated Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below